Daiichi Sankyo France SAS is a pharmaceutical group that operates in the development and commercialization of therapeutic solutions, self-described as being among the top pharmaceutical companies globally.

Daiichi Sankyo France SAS

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Viatris Inc.

biosyn Arzneimittel GmbH is involved in the pharmaceutical and biotech sectors, specializing in trace elements, particularly high-dose selenium injections, and operates unique GMP-active ingredient manufacturing plants.

biosyn Arzneimittel GmbH

S24 Global provides medical communications services that focus on innovative strategies for conveying complex scientific information, specifically for the pharmaceutical and biotechnology sectors.

Metric
Company Name	Daiichi Sankyo France SAS	Viatris Inc.	biosyn Arzneimittel GmbH	S24 Global
Symbol		VTRS
MSH ID	FR:DAIICHI-SANKYO	COM:VIATRIS	DE:BIOSYN	UK:CO:S24GLOBAL
Market	PRIVATE	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Healthcare & Health Services	Commercial & Professional Services
Industry	Pharmaceuticals	Drug Manufacturers - Specialty & Generic	Pharmaceuticals	Healthcare & Health Services
Country	FR	US	DE	GB
Stage
Employee Count		33K
Website	daiichi-sankyo.fr	viatris.com	biosyn.de	s24global.co.uk
LinkedIn			biosyn-arzneimittel-gmbh	s24group
Founders

Metric
Market Cap	12.97B
Enterprise Value
Monthly Web Traffic		1.46K
Web Traffic Growth		0.82
Valuation
Raised Capital

Metric
Revenue		15.38B
Revenue (LTM)
Revenue (NTM)
Gross Profit		6.57B
EBITDA		4.73B
Operating Income		2.05B
Net Income		54.70M
EPS		0.05
Diluted EPS		0.05
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.42
Operating Profit Margin		0.11
EBITDA Margin		0.31
Net Profit Margin		0.00
Return on Equity		0.00
Return on Assets		0.00
Return on Capital Employed		0.04

DAII

FR:DAIICHI-SANKYO

Daiichi Sankyo France SAS

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		7.63
P/B Ratio		0.67
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		0.95
EV Multiple		-0.57

Metric
Days Sales Outstanding		88.23
Days Payables Outstanding		77.65
Days Inventory Outstanding		160.94
Operating Cycle		253.63
Cash Conversion Cycle		197.19
Asset Turnover		0.34

Metric
Operating Cash Flow		2.80B
Free Cash Flow		2.33B
Cash Flow to Debt		0.15
Operating Cash Flow/Sales		0.18
Free Cash Flow Yield		0.14

Metric
Cash & Equivalents		993.60M
Accounts Receivable		78.60M
Inventory		3.47B
Goodwill		9.87B
Debt to Capitalization		0.47
Debt to Assets		0.38
Current Ratio		1.60
Quick Ratio		1.08

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.01
R&D to Revenue		0.05
SG&A to Revenue